4,7-DIMETHYL-2-(4-PYRIDINYL)-1,2,4-TRIAZOLO[1,5-a]PYRIMIDIN-5(4H)-ONE

Abstract: The compound 4,7-dimethyl-2-(4-pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidin-5(4H)-one and the pharmaceutically acceptable salts and solvates thereof are analgesic and anti-inflammatory agents. Methods for preparing and using the compound are described.

Description: 4 , 7-DIMETHYL-2-( 4-PYRIDINYL ) -1 .2 , 4- TRIAZOLO [ 1 , 5-a 1 PYRIMIDIN-5 ( 4H ) -ONE This invention is the novel chemical compound 4 , 7-dimethyl-2- ( 4-pyridin 1 ) -1 , 2 , 4-triazolo [1 , 5-a ] - pyrimidin-5 ( 4H_) -one having the structural formula : and pharmaceutically acceptable salts thereof and pharmaceutically acceptable solvates of the compound and of such salts. The invention also covers pharmaceu¬ tical compositions containing the compound or its pharmaceutically acceptable salts or solvates in combination with a pharmaceutically acceptable carrier and a method for treating pain or- inflammation in a mammal comprising administering an effective amount of the compound or its salts or solvates to said mammal. The compound 4,7-dimethyl-2-(4-pyridinyl)- l,2,4-triazolo[l,5-a]pyrimidin-5(4jH)-one may be prepared by condensing 5-(methylamino)-3-(4-pyridinyl)- lH_-l,2,4-triazole with an alkyl acetoacetate. preferably ethyl acetoacetate. Other lower alkyl esters, such as methyl, propyl, n-butyl, etc. may also be used. The condensation produces two isomeric products. The production of the desired isomer may be maximized by performing the condensation without the use of a solvent at elevated temperature. For example in a preferred method, a 2 to 5 molar excess of the alkyl acetoacetate may be utilized in place of a ' solvent. The starting material, 5-(methylamino)-3-(4- pyridinyl)-lH^l,2,4-triazole may be prepared by known methods. For example, methods described in Acta Chemica Scandinavica, 19, 1135 (1965) and art recognized modifications thereof may be utilized. The compound of the invention, 4,7-dimethyl- 2-(4-pyridin 1)-1,2,4-triazolo[1,5-a]pyrimidin-5( H) - one can form salts with pharmaceutically acceptable acids such as hydrochloric, methanesulfonic, sulfuric, phosphoric and the like. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conven¬ tional manner. The free base form may be regenerated by treating the salt forms with a base. For example, dilute aqueous base solutions may be utilized. Dilute aqueous sodium hydroxide, potassium carbonate, ammonia, and sodium bicarbonate solutions are' suitable for this purpose. The free base form differs from the respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to the respective free base form. The compound of the invention and its corresponding salts can exist in unsolvated as well as .« solvated forms, including hydrated forms. A preferred hydrate is the dihydrate. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like are equivalent to the unsolvated forms. For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, .suspending agents, binders or tablet disintegrating agents; it can also be an encapsulating material. The powders and tablets preferably contain from 5 or 10 to about 70 percent of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxy ethyl- cellulose, a low melting wax, cocoa butter and the like. For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. . The molten homogeneous mixture is then poured into conveniently sized molds, allowed to cool and thereby solidify. Liquid form compositions include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Liquid preparations can also be formulated in solution with aqueous polyethylene glycol. Aqueous solutions suitable for oral use can be prepared by adding the compound to water and adding suitable colorants, flavors, stabilizing, sweetening, solubilizing and thickening agents as desired. The quantity of active compound in a unit dose of composition may be varied or adjusted from 1 mg to 1000 mg according to the particular application and the potency of the active ingredient. The compositions can, if desired, also contain other therapeutic agents. The dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated and the particular compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. The analgesic effect of the compound of the invention 4,7-dimethyl-2-(4-pyridinyl)-1,2,4- triazolo[l,5-a]pyrimidin-5(4H)-one, (^ompound) was measured using two methods that have been well- described in the literature as indicative of pain- • relieving efficacy. First, the C_pmpound was evaluated for its ability to block writhing induced by the intraperitoneal injection of a noxious agent (acetic acid). This method has been described by others (see references, infra). Briefly, groups of five mice (CF1 male, 20-26 g) were injected intraperitoneally with 0.6% aqueous acetic acid (10 ml/kg) at fifteen minutes after the oral administration of various doses of either the C_ompound or vehicle (0.4% aqueous methylcellulose, injection volume was 20 ml/kg po). The mice were then placed in a large observation beaker, and the number of writhes for each animal was counted during a 10 minute period three minutes after the acetic acid treatment. (A writhe is defined as a sequence of arching of the back, pelvic rotation and hindlimb extension.) A mouse was considered protected if it had 50% less incidence of writhes than the average of the concomittantly run vehicle control group. At each drug dose the number of mice protected was divided by the total number of mice in the group at that dose and multiplied by 100 to give the Percent Protected for that dose. These data were used to determine the ED^ Q and 95% confidence limits according to Litchfield and Wilcoxon (infra). The second test used to determine the analgesic effects of the _Cpmpound was the rat yeast-paw test (Randall and Selitto, infra). Male, Sprague- Dawley rats (150-200 g) from Charles River Breeding Laboratories Inc. (Wilmington, MA) were used throughout. Groups of rats were first tested for their reaction times to withdraw from pressure applied with an accelerating (20 mm Hg/sec) bullet-shaped piston to each rear paw (preyeast reaction time). Subsequently, the right- rear paw was inflamed by a subplantar injection (0.1 ml) of a 20% Brewer's yeast solution (w/v in distilled r^O). Sixty minutes later the latency to withdrawal was measured again (postyeast reaction time). The Compound or vehicle was then administered and reaction times were redetermined at appropriate intervals (postdrug reaction times). A 15- sec cutoff was employed. The ED 7sec was defined as that dose needed to increase the response latencies of the inflamed paws to 7 seconds. This time was chosen because it is the approximate response latency of a normal, non-inflamed paw. In comparison, the latency of the inflamed paw of a vehicle-treated rat was approximately 1.5 sec. The ED 7sec and its 95% confidence limits were calculated using a regression analysis according to Brownlee (infra). The EDg Q of the Compound in the mouse acetic acid writhing test was determined to be 34.0 mg/kg po, with 95 percent confidence limits being between 10.2 and 56.6 mg/kg po. The ED"7 sec of the ^ Compound in the rat yeast-paw test was determined to be 12.3 mg/kg po at 30 minutes post-treatment, with 95 percent confidence limits being between 5.7 and 26.4 mg/kg po. References Mouse Acetic Acid Writhing Test Hendershot, L.C. and Forsaith, S.: Antagonism in the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and non-analgesics. J. Pharmacol. Exp. Ther. 125.237-240, 1959. Koster, R. , Anderson, M. and DeBeer, E.J.: Acetic acid for analgesic screening. Fed. ' Proc. 18; 412,1959. Litchfield, J.T. , and Wilcoxon, F. : A simplified method of evaluting dose-effect experiments. J. Pharmacol. Exp. Ther. 96: 99-113, 1949. Rat Yeast-Paw Test Brownlee, K.A.: Statistical theory and methodology. In Science and Engineering, ed. by K.A. Brownlee, pp. 145-162, John Wiley & Sons, Inc., New York, 1965. Chipkin, R.E., Iorio, L.C., Latranyi, M.B. and Barnett, A.: Direct analgesic effects of Z-prolyl-D-leucine and Z-prolyl-L-leucine in the rat yeast-paw test. J. Pharmacol. Exp. Ther. 226: 164-170, 1983. Randall, L.O. and Selitto, J.J.: A method of measurement of analgesic activity on inflamed tissue. Arch. Int. Phar acodyn Ther., Ill: 409-419, 1957. The compound of the invention and the pharma¬ ceutically acceptable salts thereof are orally effective analgesic agents. The amount and frequency of administration will be regulated according to the judgement of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptom being treated. A typical recommended dosage regimen is oral administration of from 75 to 1200 mg/day, preferably 150 to 600 mg/day, in two to four divided doses to achieve relief of the symptoms. The compound of the invention and the pharmaceutically acceptable salts thereof are also useful for treating inflammation. The anti- inflammatory use may be demonstrated by standard test procedures known in the art. PREPARATIVE EXAMPLE 1 4-Pyridinecarboxylic acid 2-[(methylamino)- iminometh 1]hydrazide Methylcarbamimidothioic acid methyl ester monohydriodide (33.0 gm) (prepared by the procedure given in Chem. Abst. , 56,-583lg, 1962). was added to cold aqueous 1N_ sodium hydroxide (142 ml). 4- Pyridinecarboxylic acid hydrazide (19.5 gm) was added to the cold solution with stirring. The reaction mixture was allowed to warm to room temperature and stirred for 72 hours. The solid product was collected by filtration, washed with a small amount of cold water and vacuum dried to give 24.0 gm. Recrystallization from methanol and vacuum drying at 100 β C gave 4- pyridiπecarboxylic acid 2-[(methylamino)imino ethyl]- hydrazide with m.p. 212-215°C dec. Anal. Calculated for CgH-^ gO C,49.73; H,5.74; N,36.25. Found: C,49.58; H,5.63? N,36.38. PREPARATIVE EXAMPLE 2 5-(Methylamino)-3-(4-pyridinyl)-1H-1,2 ,4-triazole A solution of 4-pyridinecarboxylic acid 2- [(methylamino).iminomethy1]hydrazide (6.50 g) in aqueous 1N_ sodium hydroxide (45 ml) was heated at reflux for 2..5 hours. The solution was cooled in an ice bath and neutralized by addition of glacial acetic acid. The solid product was collected by filtration and va-cuum dried to give 4.37 gm. Recrystallization from methanol and vacuum drying at 100°C gave 5-(methylamino)-3-(4- pyridinyl)-lH_-l,2,4-triazole. m.p. 228-230°C. Anal. Calculated for CgH 9 N 5 : C,54.84; H,5.18; N,39.98. Found: C,54.75; H,5.15; N,40.09. EXAMPLE 4,7-Dimethyl-2-(4-pyridinyl)-1,2,4- triazolo[l,5-a1 yrimidin-5(4H)-one A mixture of 5-(methylamino)-3-(4-pyridinyl)- lH_-l,2,4-triazole (10.5 gm) and ethyl acetoacetate (30.0 ml) was heated with stirring in an oil bath at 180°C for 30 minutes. The mixture was cooled and ethanol (100 ml) was added. The solid material was collected by filtration and vacuum dried to give 13.3 gm of a mixture of isomers. This material was recrystallized three times from ethanol to give 4,7- dimethyl-2-(4-pyridinyl)-1,2,4-triazolo[1,5 a]pyrimidin-5(4J3_)-one, m.p. 195-197°C, after vacuum drying at 100°C. Anal. Calculated for C 12 H ll N 5 0ϊ C ' 59.74; H,4.60; N,29.03. Found: C59.48; H,4.67; N,29.35. Alternatively, column chromatography of the mixture of isomers on silica gel and elution with ethyl acetate gave 4,7-dimethyl-2-(4-pyridinyl)-l,2,4- triazolo[l,5-a]pyrimidin-5(4H)-one, after recrystal¬ lization from ethanol and vacuum drying at 100°C. Elution with ethyl acetate methanol (4:1) gave the isomeric product, 4,5-dimethyl-2-(4-pyridinyl)-l,2,4- triazolo[l,5-a]pyrimidin-7(4jl_)-one, m.p. 263-267°C, after recrystallization from ethanol and vacuum drying. Anal. Calculated for c i2 H ll N 5 0: 0,59.74; H,4.60; N,29.03. Found: ' C59.58; H,4.67; N,29.24. . The following formulations exemplify some of the dosage forms of the compositions of this invention. In each, the term "active compound" designates the compound, 4,7-dimethyl-2-(4-pyridinyl)- 1,2,4-triazolo [1,5-a]pyrimidin-5(4H)-one or a pharmaceutically acceptable salt, or a solvate of the compound or such salt. Pharmaceutical Dosage Form Examples Example A Tablets No. Ingredient mg/tablet mg/tablet 1. Active Compound 100 500 2. Lactose USP 122 113 3. Corn Starch, Food Grade, 30 40 as a 10% paste in Purified Water 4. Corn Starch, Food Grade 45 40 5. Magnesium Stearate 3 7 Total 300 700 Procedure Mix item nos. 1 and 2 in a suitable mixer for 10-15 minutes. Granulate the mixture with item no. 3. Mill the damp granules through a coarse screen (e.g., 1/4") if needed. Dry the damp granules. Screen the dried granules if needed and mix with item no. 4 and mix for 10-15 minutes. Add item no. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size- and weight on a suitable tablet machine. Exa ple B Capsules No. Ingredient mg/capsule mg/capsule 1. Active Compound 100 500 2. Lactose USP 106 123 3 " . Corn Starch, Food Grade, 40 70 4. Magnesium Stearate NF 4 7 Total 250 700 Procedure Mix item nos. 1, 2 and 3 in a suitable blender for 10- 15 minutes. Add item no. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine. Example C Parenteral Ingredient mg/vial mg/vial Active Compound Sterile Powder 100 500 Add sterile water for injection or bacteriostatic water for injection for reconstitution. Example- D Injectable Ingredient mq/vial mg/vial Active Compound 100 500 Methylparaben 1.8 1.8 Propylparben 0.2 - 0.2 Sodium Bisulfite 3.2 3.2 Disodium Edetate 0.1 0.1 Sodium Sulfate 2.6 2.6 q.s. ad 1.0 ml 1.0 ml Procedure 1. Dissolve parabens in a portion (85% of the final volume) of the water for injection at 65-70°C. 2. Cool to 25-35°C. Charge and dissolve the sodium bisulfite, disodium edetate and sodium sulfate. 3. Charge and dissolve the active compound. 4. Bring the solution to final volume by adding water for injection. 5. Filter the solution through a 0.22 membrane and fill into appropriate containers. 6. Terminally sterilize the units by autoclaving. The relevant teachings of all published references cited herein are incorporated by reference.

Claims: CLAIMS: 1. The compound 4,7-dimethyl-2-(4-pyridinyl)- 1,2,4-triazolo[1,5-a]pyrimidin-5(4Jj_)-one, having the structural formula pharmaceutically acceptable salts thereof, and pharma¬ ceutically acceptable solvates of the compound and of such salts. 2. The compound or salt as defined in claim 1 in the form of a pharmaceutically acceptable solvate. 3. The solvate as defined in claim 2, said solvate being a hydrate. 4. The solvate as defined in claim 3, said solvate being a dihydrate.. 5. A pharmaceutical composition comprising as an active ingredient a compound as defined in any one of claims 1 to 4, in combination with a pharmaceutically acceptable carrier. 6. Process for preparing pharmaceutical compo¬ sitions comprising mixing a compound as defined in any one of claims 1 to 4 with a suitable pharmaceutically acceptable carrier. 7. A method for treating pain in a mammal which comprises administering an effective amount of a compound as defined in any one of claims 1 to 4. 8. A method for treating inflammation in a mammal which comprises administering an effective amount of a compound as defined in any one of claims 1 to 4. 9. A method for making 4,7-dimethyl-2-(4- pyridiny1)-1,2,4-triazolo[1,5-a3pyrimidine-5(4H_)-one having the structural formula: and its pharmaceutically acceptable salts and pharma¬ ceutically acceptable solvates of the compound and of such salts comprising: reacting 5-(methylamino)-3-(4-pyridinyl)-1H_- 1,2,4-triazole with an alkyl acetoacetate followed by isolating the compound of formula I and, if desired, converting it to a pharmaceutically acceptable salt, or a solvate of the compound or of such salt. 10. The process of claim 8 wherein the reaction is carried out at elevated temperature.

Inventors: CHIPKIN RICHARD ERIC, WITKOWSKI JOSEPH THEODORE, CHIPKIN, RICHARD, ERIC, WITKOWSKI, JOSEPH, THEODORE
Applicants: SCHERING CORP, SCHERING CORPORATION
Application year: 1984
Main classification: C07D487
IPC codes: C07D213, C07D401, C07D487